Shawn Morales

Aurinia Pharmaceuticals, Inc.
Temecula, CA, United States

a

Disclosure information not submitted.

Presentation(s):

• 1629: AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases

  Monday, November 14, 2022
  9:00 AM – 9:10 AM Eastern Time